期刊文献+

乳腺癌细胞中p53、C-erbB-2、p21^(WAF1)和CDK4的表达及临床意义 被引量:8

Expression and clinical significance of p53,C-erbB-2,p21^(WAF1) CDK4 in breast cancer tissue
下载PDF
导出
摘要 目的:探讨乳腺癌组织中p53、C-erbB-2、p21WAF1和CDK4的表达及临床意义。方法:采用免疫组化SP法检测120例乳腺癌组织石腊切片上p53、C-erbB-2、p21WAF1和CDK4的表达。结果:p53、C-erbB-2、p21WAF1和CDK4阳性表达率分别为53.3%、63.3%、58.3%、41.6%;阳性产物主要位于细胞核中,p53、C-erbB-2的表达与肿瘤组织分级(P<0.05)、淋巴结转移(P<0.01)显著相关,p21WAF1的表达与淋巴结转移(P<0.01)显著相关,无淋巴结转移组明显高于有淋巴结转移组;与组织分级及PR、ER表达无显著相关。CDK4阳性表达与肿瘤组织分级(P<0.05)、淋巴结转移(P<0.01)显著相关,与PR、ER无相关。结论:p53、C-erbB-2、p21WAF1和CDK4与乳腺癌的发生发展密切相关,可作为判断肿瘤浸润转移、指导治疗和估计预后的参考指标。特别是p53的表达水平及淋巴结转移可能是判断乳腺癌的术后生存的独立有效指标,而综合应用上述指标可能更有助于预后的判断。 Objective:To explore the expression and clinical significance of p53, C-erbB-2, p21^WAF1 and CDK4 in breast cancer tissue. Methods:The level of p53, C-erbB-2, p21^WAF1 and CDK4 were detected with immunohistochemical staining method in 120 breast tissues species. The relationship between p53, C-erbB-2, p21^WAF1, CDK4 and some clinicopathologic factors were analyzed. Results:P53, C-erbB-2, p21^WAF1, CDK4 were mostly expressd in nucleus with rates of 53.3% ,63.3%,58.3% ,41.6% respectively. The expression level of p53, C-erbB-2 was significantly correlated with histological grade (P 〈 0.05 ) and axillary lymph node metastases (P 〈 0.01). The p21^WAF1 expression was related with lymph node metastasis (P 〈 0.01), while not related with clinicopathologic characteristics such as histological grade, PR and ER status (P 〉 0.05). The expression of CDK4 was correlated with histological grade(P 〈 0.01 ). and lymph node metastasis status(P 〈 0.01 ),while not correlated with PR and ER status(P 〉 0.05). Conclusion: The gene products of p53, C-erbB-2, p21^WAF1, CDK4 play a key role in the oncogenesis and development of breast cancer. Their expression could be useful indexes to assess the malignant level and clinical prognosis of breast carcinoma. The expression of p53 and axillary lymph node metastases may be dependent prognostic indicators of operative survival for patients with breast cancer. The combined use of the above markers may be helpful in making a better estimation of prognosis.
出处 《南京医科大学学报(自然科学版)》 CAS CSCD 北大核心 2007年第1期70-73,I0001,共5页 Journal of Nanjing Medical University(Natural Sciences)
基金 江苏省卫生厅重大科研资助项目(13548)
关键词 P53 C-ERBB-2 P21WAF1 CDK4 乳腺癌 基因表达 肿瘤转移 p53 C-erbB-2 p21^WAF1 CDK4 breast carcinoma
  • 相关文献

参考文献11

  • 1Rau B,Sturm I,Lage H,et al,Dynamic expression profile of p21WAF1/CIP1 and Ki-67predicts survival in rectal carcinoma treated with reoperative radiochemotherapy[J].J Clin Oncol,2003,21 (18):3391-3401.
  • 2Elkablawy MA,Maxwell P,Williamson K,et al.Apoptosis and cell-cycle regulatory proteins in colorectal carcinoma:relationship to tumor stage and patient survival[J].J Pathol,2001,194(4):436-443.
  • 3Bearss DJ,Lee RJ,Troyer DA,et al.Differential effects of p21 (WAF1/CIP1) deficiency on MMTV-ras and MMTV-myc mammary tumor properties[J].Cancer Res,2002,62:2077-2084.
  • 4陈建国,段惠军,王玉珍.p16、p21^(WAF1/CIP1)、CyclinD1表达与乳腺癌病理特征[J].肿瘤,2001,21(3):205-207. 被引量:15
  • 5Li R,Waga S,Hannon GJ,et al.Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair[J].Nature,1994,371:534-537.
  • 6陈琳,杨金巧,幸天勇,武正炎.乳腺癌中C-erbB2癌基因、PS2表达及其临床意义研究[J].南京医科大学学报(自然科学版),2005,25(12):936-939. 被引量:2
  • 7史金兰,陈萍倩,林裕媛,朱明月,张蓉,赵华,薛苏华.乳腺癌雌孕激素受体与C-erbB-2、p53、nm23基因表达及相关分析[J].实用肿瘤学杂志,2001,15(1):10-12. 被引量:19
  • 8Stewart MC,Kadlcek RM,Robbins PD,et al.Expression and activity of the CDK inhibitor p57 kip2 in chondrocytes undergoing hypertrophic differentiation[J].J Bone Miner Res,2004,19(1):123-132.
  • 9Gong J,Ammanamanchi S,Ko TC,et al.Transforming growth factor beta 1 increases the stability of p21/WAF1/CIP1 protein and inhibits CDK2 kinase activity in human colon carcinoma FET cells[J].Cancer Res,2003,63 (12):3340-3346.
  • 10Yan Z,Deng X,Friedman E.Oncogenic Ki-ras confers a more aggressive colon cancer phenotype through modification of transforming growth factor-beta receptor Ⅲ[J].J Biol Chem,2001,276(2):1555-1563.

二级参考文献21

  • 1刘晓光,徐光炜.c—erbB— 2、p^(53)及nm23基因及产物在乳腺癌预后中的意义[J].中国肿瘤临床,1994,21(5):391-395. 被引量:15
  • 2杨帆,中国癌症杂志,1997年,7卷,165页
  • 3郭山春,中华医学杂志,1997年,77卷,529页
  • 4Nobori T,Nature,1994年,368卷,753页
  • 5Lian SC, Tan PH. CerbB2 status in breast cancer:pathologic issues [J]. Ann Acad Med Singapore, 2002,31 (6): 793-798.
  • 6Slamon DJ, GM Clark, SG Wong, et al. Human breast cancer:. Correlation of relapse and survival with amplification of the HER-2/neu oncogene [J]. Science,1987, 235(4785):177-182.
  • 7Serra C, Vizoso F, Alonso L, et al. Expression and prognostic significance of lysozyme in male breast cancer [J]. Breast Cancer Res, 2002, 4(6): R16.
  • 8Thompson AM, Hawkins RA, Elton RA, et al. PS2 is an independent factor of good prognosis in primary breast cancer[J]. Br J Cancer, 1993, 68(1): 93-96.
  • 9Kallioniemi OP. Association of C-erbB2 protein overexpression with high rate of cell proliferation,increased risk of visceral metastasis and poor longterm survival in breast cancer[J]. Int J Cancer, 1991, 49(5):650-655.
  • 10Tsutsui S, Ohno S, Murakami S, et al. Prognostic value of c-erbB2 expression in breast cancer [J]. J Surg Oncol,2002, 79(4): 216-223.

共引文献33

同被引文献77

引证文献8

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部